Endovasc Receives US Patent Protecting Its Muscle Mass Technology.HOUSTON -- Endovasc Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : EVSC EVSC Evansville Vanderburgh School Corporation , OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). : EVSD), today announced that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has granted the Company a patent entitled "Development of Muscle Mass in a Mammal." The patent number is US 7,074,812 B2. Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer, commented, "We are extremely pleased to receive this patent protecting one of our key technologies. The expansion of our intellectual property portfolio is critical to our long-term success and this is a very positive development while we are working diligently toward the final phase of testing for our drug Liprostin." About Endovasc, Inc. Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent stent (stent) 1. a device or mold of a suitable material, used to hold a skin graft in place. 2. a slender rodlike or threadlike device used to provide support for tubular structures that are being anastomosed, or coating technology; and Nutraceutical Development Corporation. For more information about Endovasc, please visit www.endovasc.com. This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion